Insights

Transparency Rising applauds the passage of the bipartisan government funding bill.  The PBM reform language included in the package is an important first step in helping to foster lower prices for patients and the business community and should promote meaningful competition and clarity.   These policy changes are a valuable market correction for a drug supply chain dominated by exclusionary conduct, opacity, and the hidden off shoring of American patient discounts in foreign countries.   Critically, we also believe these reforms align with and bolster key provisions of President Trump’s recently announced great healthcare plan, and specifically his powerful focus on middlemen, PBM rebates, and aligned brokers, as the Administration works to build of an American, and more...